GlassScriptPhysician profile
Etan Milgrom
NPI 1649281130
$7,981.28
in general payments reported to CMS, 2019-2025
25 companies · $2,238 in 2025
The $2,238 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $311 · 2021: $766 · 2022: $1,371 · 2023: $1,329 · 2024: $1,842 · 2025: $2,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,253 · Education: $129 · Consulting Fee: $27.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,252.51 |
| Education | $129.09 |
| Consulting Fee | $27.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,327.60 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,296.20 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,075.27 | 2020-2025 | Fasenra, Tezspire |
| Csl Behring | $819.00 | 2021-2025 | Andembry, Haegarda, Hizentra |
| Biocryst US Sales Co., LLC | $628.66 | 2024-2025 | Orladeyo |
| Genentech USA, INC. | $527.20 | 2021-2025 | Xolair |
| Amgen INC. | $451.29 | 2021-2025 | Tezspire, Actimmune |
| Glaxosmithkline, LLC. | $403.81 | 2023-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $268.98 | 2020-2022 | |
| Cycle Pharmaceuticals INC | $225.68 | 2025 | Sajazir |
| Octapharma USA, INC. | $204.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $157.47 | 2023-2025 | |
| Ionis Pharmaceuticals, INC. | $150.80 | 2025 | Dawnzera |
| Kyowa Kirin, INC. | $102.18 | 2025 | |
| Alk-Abello, INC | $84.52 | 2023-2025 | Odactra, Ragwitek, Grastek |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $38.39 | 2023 | Xembify |
| Lilly USA, LLC | $33.53 | 2025 | Ebglyss |
| Optinose US, INC. | $32.63 | 2023 | |
| Adma Biomanufacturing LLC | $27.14 | 2024 | |
| Pfizer INC. | $25.08 | 2021 | |
| Covis Pharma Gmbh | $24.96 | 2022 | |
| Kaleo, INC. | $23.31 | 2021 | |
| Incyte Corporation | $21.10 | 2023 | Opzelura |
| Bio Products Laboratory USA, INC. | $18.87 | 2022 | |
| Philips North America LLC | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Etan Milgrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.